Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document 52024M11486

Prior notification of a concentration (Case M.11486 – NOVO HOLDINGS / NOVO NORDISK / CATALENT)

PUB/2024/1108

OJ C, C/2024/6837, 11.11.2024, ELI: http://data.europa.eu/eli/C/2024/6837/oj (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

ELI: http://data.europa.eu/eli/C/2024/6837/oj

European flag

Official Journal
of the European Union

EN

C series

C/2024/6837

11.11.2024

Prior notification of a concentration

(Case M.11486 – NOVO HOLDINGS / NOVO NORDISK / CATALENT)

(Text with EEA relevance)

(C/2024/6837)

1.   

On 31 October 2024, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).

This notification concerns the following undertakings:

—

Novo Holdings A/S (‘Novo Holdings’, Denmark),

—

Novo Nordisk A/S (‘Novo Nordisk’, Denmark), controlled by Novo Holdings,

—

Catalent, Inc. (‘Catalent’, U.S.).

Novo Holdings will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Catalent. Subsequently, Catalent’s sites in Brussels (Belgium), Anagni (Italy), and Bloomington (U.S.) will be transferred to Novo Nordisk.

The concentration is accomplished by way of purchase of shares.

2.   

The business activities of the undertakings concerned are the following:

—

Novo Holdings is a holding and investment company responsible for the management of the assets of Novo Nordisk Fonden, which owns 100 % of the shares of Novo Holdings, through strategic investments in the life sciences and related areas and through investments of a financial and venture capital nature in a broad portfolio of companies,

—

Novo Nordisk is a global healthcare company with a focus on developing treatments for metabolic disorders such as diabetes and obesity, as well as chronic diseases such as inter alia, haemophilia and growth disorders,

—

Catalent is a global contract development and manufacturing organisation which provides third-party development and manufacturing solutions to companies in the pharmaceutical, biotech, and consumer health industries.

3.   

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4.   

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.11486 – NOVO HOLDINGS / NOVO NORDISK / CATALENT

Observations can be sent to the Commission by email or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Postal address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

(1)   OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

ELI: http://data.europa.eu/eli/C/2024/6837/oj

ISSN 1977-091X (electronic edition)

Top